ArticleMicrobial cell factories2021
Strategy for mass production of lytic Staphylococcus aureus bacteriophage pSa-3: contribution of multiplicity of infection and response surface methodology.
Article in Microbial cell factories, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Bacteriophage-Based Therapeutic, Diagnostic, and Biocontrol Platforms: Engineering, Evidence, and Translational Challenges.International journal of molecular sciences · 2026Review
- The amplification of bacteriophages using Salmonella YB1 as a host and its therapeutic efficacy against salmonellosis in broilers.Poultry science · 2026Article
- A novel phage preparation capable of simultaneously inhibiting both K1 and K2 serotypes ofApplied and environmental microbiology · 2026Article
- Enhancing propagation and purification efficiency of M13 bacteriophage for improved phage display applications.Biology methods & protocols · 2026Article
- Comparison of the genomes of Vibrio phages pVco-5 and pVco-7: implications for phage-host interactions.Archives of virology · 2025Article
- Two novel polyvalent phages: a promising approach for cross-order pathogen control in aquaculture.Virology journal · 2025Article
- Efficacy of a commercial bacteriophage cocktail against planktonic cells and both thin and thick biofilms of skin pathogens, measured using isothermal microcalorimetry.Frontiers in microbiology · 2025Article
- Standardization of the Agar Plate Method for Bacteriophage Production.Antibiotics (Basel, Switzerland) · 2024Article
- Optimization of the large-scale production for Erwinia amylovora bacteriophages.Microbial cell factories · 2024Article
- Optimizing phage-based mutant recovery and minimizing heat effect in the construction of transposon libraries in Staphylococcus aureus.Scientific reports · 2024Article
- Optimizing the formulation ofHeliyon · 2023Article
- The Biotechnological Application of Bacteriophages: What to Do and Where to Go in the Middle of the Post-Antibiotic Era.Microorganisms · 2023Review
- Characterization ofFood science and biotechnology · 2023Article
- Article
- Design of respirable sprayed microparticles of encapsulated bacteriophages.Frontiers in drug delivery · 2023Review
- Statistical optimization of a podoviral anti-MRSA phage CCASU-L10 generated from an under sampled repository: Chicken rinse.Frontiers in cellular and infection microbiology · 2023Article
- Phage Cocktail in Combination with Kasugamycin as a Potential Treatment for Fire Blight Caused byAntibiotics (Basel, Switzerland) · 2022Article
- Prolongation of Fate of Bacteriophages In Vivo by Polylactic-Co-Glycolic-Acid/Alginate-Composite Encapsulation.Antibiotics (Basel, Switzerland) · 2022Article
- Phage Therapy againstPharmaceutics · 2022Article
- Isolation and characterization of vB_XciM_LucasX, a new jumbo phage that infects Xanthomonas citri and Xanthomonas fuscans.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAntibiotic-resistant bacteria have emerged as a serious problem; bacteriophages have, therefore, been proposed as a therapeutic alternative to antibiotics. Several authorities, such as pharmacopeia, FDA, have confirmed their safety, and some bacteriophages are commercially available worldwide. The demand for bacteriophages is expected to increase exponentially in the future; hence, there is an urgent need to mass-produce bacteriophages economically. Unlike the replication of non-lytic bacteriophages, lytic bacteriophages are replicated by lysing host bacteria, which leads to the termination of phage production; hence, strategies that can prolong the lysis of host bacteria in bacteria-bacteriophage co-cultures, are required.
resultsIn the current study, we manipulated the inoculum concentrations of Staphylococcus aureus and phage pSa-3 (multiplicity of infection, MOI), and their energy sources to delay the bactericidal effect while optimizing phage production. We examined an increasing range of bacterial inoculum concentration (2 × 10
conclusionsTherefore, Staphylococcus phage pSa-3 production can be maximized by increasing the bacterial inoculum and reducing the seeding phage MOI, and this combinatorial strategy could decrease the phage production time. Further, we suggest that response surface methodology has the potential for optimizing the mass production of lytic bacteriophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.